In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.
Spero will hold rights to the antibody in all markets except Mainland China, Hong Kong, Macau, and Taiwan.
The decision is based on results from the Phase III MAJESTY study.
The partnership is an extension of over 12 months of technical engagement between the two companies.
Cellares will adapt and automate the SBT-77-7101 manufacturing process from Sonoma for use with Cell Shuttle.
Patient advocates in remission from MCL and FL discuss their experiences with treatment, as well as their views on CAR-T therapy’s place in managing blood cancers.
